BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32651027)

  • 1. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
    Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
    Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
    Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
    Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA expression and association with the clinicopathological characteristics in papillary thyroid carcinoma.
    Guo D; Li F; Zhao X; Long B; Zhang S; Wang A; Cao D; Sun J; Li B
    Oncol Rep; 2020 Aug; 44(2):519-532. PubMed ID: 32468074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
    Kombak FE; Özkan N; Uğurlu MÜ; Kaya H
    Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E, BANCR, miR-203a-3p and miR-204-3p in Risk Stratification of PTC Patients.
    Stojanović S; Šelemetjev S; Đorić I; Janković Miljuš J; Tatić S; Živaljević V; Išić Denčić T
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
    Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
    Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
    Chen B; Shi Y; Xu Y; Zhang J
    Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
    Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
    Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
    Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
    Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of BANCR in the relationship between Hashimoto's thyroiditis and papillary thyroid carcinoma expression patterns and possible molecular mechanisms.
    Zhang J; Yao L; Guo Y
    J Gene Med; 2024 Feb; 26(2):e3663. PubMed ID: 38342961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.